Evaluating Acridones as Novel Therapeutics for Human Babesiosis

Human babesiosis is an emerging tick-borne disease caused by Babesia parasites, most notably Babesia microti and Babesia duncani in North America and Babesia divergens in Europe. Infections can be severe, persistent, or relapse despite treatment, and current therapeutic options remain limited, underscoring the urgent need for new and effective treatment options.

Acridone derivatives, originally developed as potent antimalarial agents against multiple life cycle stages of the malaria parasites, were evaluated for their antibabesial activity using continuous in vitro culture systems of B. duncani and B. divergens . Lead candidates were assessed for selectivity against human cell lines to establish preliminary safety profiles, and select compounds were further advanced into preliminary in vivo efficacy studies using murine models of B. duncani and B. microti babesiosis to assess their therapeutic potential.

Nine prioritized acridone derivatives demonstrated potent in vitro activity against both B. duncani and B. divergens , accompanied by favorable selectivity indices relative to human cell lines. However, in vivo evaluation of representative compounds did not achieve parasite clearance in murine models. Structure-activity relationship (SAR) analyses highlighted key structural features that are critical for maintaining antibabesial potency and offer guidance for further lead optimization.

Acridone derivatives show strong in vitro antibabesial activity and represent promising lead chemotypes for therapeutic development. To advance these candidates, future studies focused on optimizing their pharmacokinetic properties, improving in vivo efficacy, and evaluating synergistic combination regimens will be essential for progressing toward effective treatments for human babesiosis.